MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319855 | Name: Pozanicline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pozanicline, also known as ABT-089, is a nootropic and neuroprotective agent under development for the treatment of ADHD. Pozanicline binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype, but not the α7 and α3β4 subtypes familiar to nicotine. Pozanicline has particularly low tendency to cause side effects compared to other drugs in the class.

Chemical Structure

Pozanicline
Pozanicline
CAS#161417-03-4 (free base)

Theoretical Analysis

MedKoo Cat#: 319855

Name: Pozanicline

CAS#: 161417-03-4 (free base)

Chemical Formula: C11H16N2O

Exact Mass: 192.1263

Molecular Weight: 192.26

Elemental Analysis: C, 68.72; H, 8.39; N, 14.57; O, 8.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
945405-37-8 (tartrate) 161417-03-4 (free base)
Synonym
ABT-089; ABT 089; ABT089; A-87089; A-87089.0; Pozanicline
IUPAC/Chemical Name
2-Methyl-3-(2S-pyrrolidinylmethoxy)pyridine
InChi Key
YRVIKLBSVVNSHF-JTQLQIEISA-N
InChi Code
InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3/t10-/m0/s1
SMILES Code
CC1=NC=CC=C1OC[C@H]2NCCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 192.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yildirim E, Connor DA, Gould TJ. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. Behav Pharmacol. 2015 Apr;26(3):241-8. doi: 10.1097/FBP.0000000000000111. PubMed PMID: 25426579; PubMed Central PMCID: PMC4459497. 2: Childress A, Sallee FR. Pozanicline for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Nov;23(11):1585-93. doi: 10.1517/13543784.2014.956078. Epub 2014 Sep 6. Review. PubMed PMID: 25196198. 3: Lee AM, Arreola AC, Kimmey BA, Schmidt HD. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. Behav Brain Res. 2014 Nov 1;274:168-75. doi: 10.1016/j.bbr.2014.08.016. Epub 2014 Aug 14. PubMed PMID: 25128791; PubMed Central PMCID: PMC4179987. 4: Yohn NL, Turner JR, Blendy JA. Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther. 2014 May;349(2):348-54. doi: 10.1124/jpet.113.211706. Epub 2014 Mar 13. PubMed PMID: 24627467; PubMed Central PMCID: PMC3989801. 5: Zhang D, Bordia T, McGregor M, McIntosh JM, Decker MW, Quik M. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord. 2014 Apr;29(4):508-17. doi: 10.1002/mds.25817. Epub 2014 Feb 11. PubMed PMID: 24515328; PubMed Central PMCID: PMC3990279. 6: Paolone G, Angelakos CC, Meyer PJ, Robinson TE, Sarter M. Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. J Neurosci. 2013 May 8;33(19):8321-35. doi: 10.1523/JNEUROSCI.0709-13.2013. PubMed PMID: 23658172; PubMed Central PMCID: PMC3690461. 7: Bain EE, Apostol G, Sangal RB, Robieson WZ, McNeill DL, Abi-Saab WM, Saltarelli MD. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012 Jun;73(6):783-9. doi: 10.4088/JCP.10m06719. PubMed PMID: 22795204. 8: Scanio MJ, Shi L, Bunnelle WH, Anderson DJ, Helfrich RJ, Malysz J, Thorin-Hagene KK, Van Handel CE, Marsh KC, Lee CH, Gopalakrishnan M. Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligands. J Med Chem. 2011 Nov 10;54(21):7678-92. doi: 10.1021/jm201045m. Epub 2011 Oct 11. PubMed PMID: 21962147. 9: Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD. Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012 Feb;219(3):715-25. doi: 10.1007/s00213-011-2393-2. Epub 2011 Jul 12. PubMed PMID: 21748252. 10: Franke AG, Konrad A, Lieb K, Huss M. [Stimulant and non-stimulant medication in current and future therapy for ADHD]. Fortschr Neurol Psychiatr. 2012 Mar;80(3):130-40. doi: 10.1055/s-0031-1273223. Epub 2011 May 24. Review. German. PubMed PMID: 21611939. 11: Chin CL, Carr RA, Llano DA, Barret O, Xu H, Batis J, Koren AO, Seibyl JP, Marsh KC, Tamagnan G, Decker MW, Day M, Fox GB. Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089. J Pharmacol Exp Ther. 2011 Mar;336(3):716-23. doi: 10.1124/jpet.110.173609. Epub 2010 Dec 20. PubMed PMID: 21172907. 12: Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, Olson E, Robieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):73-84.e1. doi: 10.1016/j.jaac.2010.10.001. Epub 2010 Nov 25. PubMed PMID: 21156272; PubMed Central PMCID: PMC3757954. 13: Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M, Briggs CA. Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. Biochem Pharmacol. 2009 Oct 1;78(7):795-802. doi: 10.1016/j.bcp.2009.05.022. Epub 2009 May 27. PubMed PMID: 19481067; PubMed Central PMCID: PMC2772152. 14: Parikh V, Man K, Decker MW, Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci. 2008 Apr 2;28(14):3769-80. doi: 10.1523/JNEUROSCI.5251-07.2008. PubMed PMID: 18385335. 15: Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol. 2007 Oct 15;74(8):1212-23. Epub 2007 Jul 7. Review. PubMed PMID: 17689498; PubMed Central PMCID: PMC2974320. 16: Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006 Jun 1;59(11):1065-70. Epub 2006 Feb 23. PubMed PMID: 16499880. 17: Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 2004 Summer;10(2):167-82. Review. PubMed PMID: 15179445. 18: Bryan PD, Emry ML, El-Shourbagy TA. Determination of ABT-089 in human plasma by high performance liquid chromatography using in situ precolumn derivatization with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole. J Pharm Biomed Anal. 1999 Jun;20(1-2):49-63. PubMed PMID: 10704009. 19: Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch JM, Arneric SP, Gopalakrishnan M, Sullivan JP. Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. Eur J Pharmacol. 1999 Feb 5;366(2-3):301-8. PubMed PMID: 10082212. 20: Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl). 1998 Mar;136(1):50-8. PubMed PMID: 9537682.